The estimated Net Worth of Ankit Mahadevia is at least $2.93 Milhão dollars as of 27 August 2024. Ankit Mahadevia owns over 5,912 units of Spero Therapeutics Inc stock worth over $1,017,174 and over the last 7 years he sold SPRO stock worth over $129,008. In addition, he makes $1,785,680 as President, Chief Executive Officer, e Director at Spero Therapeutics Inc.
Sign up
Ankit Mahadevia SPRO stock SEC Form 4 insiders trading
Ankit has made over 12 trades of the Spero Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,912 units of SPRO stock worth $7,981 on 27 August 2024.
The largest trade he's ever made was selling 63,795 units of Spero Therapeutics Inc stock on 2 February 2024 worth over $87,399. On average, Ankit trades about 7,081 units every 107 days since 2017. As of 27 August 2024 he still owns at least 759,085 units of Spero Therapeutics Inc stock.
You can see the complete history of Ankit Mahadevia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ankit Mahadevia biography
Dr. Ankit Mahadevia M.D. serves as President, Chief Executive Officer, Director of the Company. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, Massachusetts. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Nimbus Therapeutics, Arteaus Therapeutics (acquired by Lilly), and Translate Bio (Nasdaq: TBIO). He led three of these companies as acting CEO, including Synlogic (Nasdaq: SYBX). Prior to joining Atlas Venture in 2008, Dr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. He has spoken widely on entrepreneurship, including at Harvard University, Columbia University, Northwestern University, and the Berkeley Forum. Dr. Mahadevia has also been active in the policy of life science innovation, including service on the Advisory Council at the NIH National Center for Advancing Translational Sciences. Dr. Mahadevia holds an M.D. from the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics and Biology from Northwestern University. Mahadevia is qualified to serve on our Board of Directors due to his experience serving as our Chief Executive Officer and President and his extensive experience in the life sciences industry.
What is the salary of Ankit Mahadevia?
As the President, Chief Executive Officer, e Director of Spero Therapeutics Inc, the total compensation of Ankit Mahadevia at Spero Therapeutics Inc is $1,785,680. There are no executives at Spero Therapeutics Inc getting paid more.
How old is Ankit Mahadevia?
Ankit Mahadevia is 39, he's been the President, Chief Executive Officer, e Director of Spero Therapeutics Inc since 2015. There are 19 older and no younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.
What's Ankit Mahadevia's mailing address?
Ankit's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Spero Therapeutics Inc
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela, eCapital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
What does Spero Therapeutics Inc do?
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
What does Spero Therapeutics Inc's logo look like?
Complete history of Ankit Mahadevia stock trades at Spero Therapeutics Inc
Spero Therapeutics Inc executives and stock owners
Spero Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ankit Mahadevia,
President, Chief Executive Officer, Director -
Dr. Ankit Mahadevia M.D., MBA,
Co-Founder, CEO, Pres & Director -
Cristina Larkin,
Chief Operating Officer and Chief Commercial Officer -
David Melnick,
Cheif Medical Officer -
Dr. David A. Melnick M.D.,
Chief Medical Officer -
Cristina Larkin,
Chief Operating Officer -
Thomas Parr,
Chief Scientific Officer -
Cynthia Smith,
Independent Director -
Milind Deshpande,
Independent Chairman of the Board -
Frank Thomas,
Independent Director -
Patrick Vink,
Independent Director -
John Pottage,
Independent Director -
Jean-Francois Formela,
Independent Director -
Sharon Klahre,
IR Contact Officer -
Scott Jackson,
Independent Director -
Timothy Keutzer,
Chief Development Officer -
Stephen DiPalma,
Chief Financial Officer, Treasurer -
Timothy Keutzer,
Chief Devel. Officer -
James P. Brady,
Chief Human Resource Officer -
David Musselman,
Sr. VP of Sales & Market Access -
Tamara Lynn Joseph L.L.M., J.D.,
Chief Legal Officer -
Ted Jenkins,
VP & Head of Investor Relations -
Dr. Thomas R. Parr Jr., Ph.D.,
Chief Scientific Officer -
Satyavrat Shukla C.F.A.,
Chief Financial Officer -
David P Southwell,
Director -
John J Gorman,
Director -
Jack Fingerhut,
President -
Allen S Greene,
Chairman of the Board and CEO -
Lager H Martin,
Director -
Joel Sendek,
Chief Financial Officer -
Plc Gsk,
10% owner -
Joseph R Fish,
EVP & Chief Technology Officer -
Leonard J Stanley,
Director -
Vikas Goyal,
Director -
Casper Breum,
Director -
Stanley P Wirtheim,
Chief Financial Officer -
Zohar Ben Dov,
10% owner -
Esther Rajavelu,
See Remarks -
Capital Management, Llc Aqu...,
-
Kathleen Tregoning,
-
Kamal Hamed,
Chief Medical Officer -
Sath Shukla,
CEO & President -
Tamara L Joseph,
Chief Legal Officer